These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

47 related articles for article (PubMed ID: 913230)

  • 41. Butaclamol in the treatment of schizophrenia. A standard-controlled clinical trial.
    Nestoros JN; Lehmann HE; Ban TA
    Int Pharmacopsychiatry; 1978; 13(3):138-50. PubMed ID: 355181
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Evaluation of butaclamol in chronic schizophrenic patients.
    Clark ML; Paredes A; Costiloe JP; Wood F
    J Clin Pharmacol; 1977; 17(8-9):529-36. PubMed ID: 19510
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Evaluation of two dose levels of loxapine succinate in chronic schizophrenia.
    Clark ML; Paredes A; Costiloe JP; Fulkerson FG; Wood F
    Dis Nerv Syst; 1977 Jan; 38(1):7-10. PubMed ID: 318984
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Minimal effective dose and relapse--double-blind trial: haloperidol decanoate vs. placebo.
    Eklund K; Forsman A
    Clin Neuropharmacol; 1991; 14 Suppl 2():S7-12; discussion S12-5. PubMed ID: 1684310
    [TBL] [Abstract][Full Text] [Related]  

  • 45. An analysis of safety and tolerability data from controlled, comparative studies of quetiapine in patients with schizophrenia, focusing on extrapyramidal symptoms.
    Timdahl K; Carlsson A; Stening G
    Hum Psychopharmacol; 2007 Jul; 22(5):315-25. PubMed ID: 17542047
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Butaclamol in newly admitted chronic schizophrenic patients: a modified fixed-dose dose-range design.
    Clark ML; Costiloe JP; Wood F; Paredes A; Fulkerson FG
    Dis Nerv Syst; 1977 Nov; 38(11):943-7. PubMed ID: 913230
    [TBL] [Abstract][Full Text] [Related]  

  • 47.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]     [New Search]
    of 3.